LX2020’s preclinical studies in a relevant murine model of PKP2-ACM demonstrated promising outcomes, with restored desmosomal integrity, reduced arrhythmias, and extended survival. The therapy delivers a functional PKP2 gene intravenously to the cardiac muscle, elevating PKP2 protein levels in the critical cardiac desmosome—a structure vital for cell adhesion.
The upcoming Phase 1/2 trial, HEROIC-PKP2, will be a first-in-human, 52-week open-label, dose-escalating, multicenter study evaluating LX2020’s safety and tolerability in adult PKP2-ACM patients. Additionally, efficacy measures will assess myocardial protein expression, cardiac structure and function biomarkers, and arrhythmia burden. LX2020 will be administered as a one-time intravenous infusion in two ascending-dose cohorts, with potential expansion, followed by long-term safety and efficacy monitoring for four years.
PKP2-ACM is characterized by myocardial cell loss, replaced by fibrotic tissue and fatty deposits, primarily caused by PKP2 gene variants, leading to heart dysfunction, rhythm abnormalities, and sudden death. Current treatments only manage symptoms and lack targeted disease intervention.
The clearance of LX2020’s IND represents a significant step toward offering a potential one-time treatment for PKP2-ACM patients, who currently lack effective therapeutic options.
LEXEO Therapeutics aims to develop effective treatments for genetically defined cardiovascular diseases and a subgroup of genetically defined Alzheimer’s disease through a diverse pipeline of AAV-based gene therapies.
Check out our AAV CDMO service to expedite your gene therapy research
PackGene is a CRO & CDMO technology company that specializes in packaging recombinant adeno-associated virus (rAAV) vectors. Since its establishment in 2014, PackGene has been a leader in the AAV vector CRO service field, providing tens of thousands of custom batches of AAV samples to customers in over 20 countries. PackGene offers a one-stop CMC solution for the early development, pre-clinical development, clinical trials, and drug approval of rAAV vector drugs for cell and gene therapy (CGT) companies that is fast, cost-effective, high-quality, and scalable. Additionally, the company provides compliant services for the GMP-scale production of AAVs and plasmids for pharmaceutical companies, utilizing five technology platforms, including the π-Alpha™ 293 cell AAV high-yield platform and the π-Omega™ plasmid high-yield platform. PackGene’s mission is to make gene therapy affordable and accelerate the launch of innovative gene drugs. The company aims to simplify the challenging aspects of gene therapy development and industrialization processes and provide stable, efficient, and economical rAAV Fast Services to accelerate gene and cell therapy development efforts from discovery phase to commercialization.
Related News
Exploring Tau Protein’s Role in Glaucoma: New Insights and Therapeutic Potential
Glaucoma, a chronic neurodegenerative disorder, leads to irreversible vision loss by damaging retinal ganglion cells (RGCs) and the optic nerve, often associated with increased intraocular pressure (IOP). Despite the benefits of IOP-lowering treatments, the underlying...
FDA-mandated CAR-T monitoring period could be halved, say researchers
In patients with diffuse large B-cell non-Hodgkin lymphoma (DLBCL), the two hallmark post-chimeric antigen receptor (CAR)-T therapy toxicities are extremely rare after two weeks, supporting a shorter, more flexible toxicity monitoring period, according to a study...
Ancestral CRISPR-Cas13 Ribonucleases Discovered: Implications for Genome Editing
In a pioneering study published in *Science*, a team of researchers led by Peter H. Yoon and Jennifer A. Doudna from the University of California, Berkeley, has made a remarkable discovery in the realm of CRISPR technology. The team has identified an ancestral clade...
KBI Biopharma Expands Manufacturing Contract with Global Pharmaceutical Company
KBI Biopharma Inc., a JSR Life Sciences company and global cGMP contract development and manufacturing organization (CDMO), has extended and expanded its manufacturing contract with a leading global pharmaceutical company. Originally initiated in 2020, the renewed...
Related Services
Plasmids GMP Services
Multiple scales & grade of solutions of various kind of plasmids suitable for multiple treatments in a fast and cost effective way.
READ MORE
AAV GMP Services
Ranging from small-scale AAV production, to large-scale AAV cGMP manufacturing for animal studies.
READ MORE
Technology Platforms
PackGene’s proprietary π-Alpha™ 293 AAV High-yield Platform increases AAV production by 3 to 8 times that of traditional platforms.
READ MORE
